Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma

(MedPage Today) -- An increased risk of early death has created uncertainty about the risk-benefit ratio of two CAR T-cell therapies for relapsed/refractory multiple myeloma, which an FDA advisory committee will consider on Friday. Both ciltacabtagene...
Source: MedPage Today Public Health - Category: American Health Source Type: news